AIM ImmunoTech Inc [AIM] stock prices are up 12.96% to $0.56 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AIM shares have gain 17.18% over the last week, with a monthly amount glided 55.00%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 10, April 2024, AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer. In a post published today on Yahoo Finance, Robert Edwards, MD, Chair of the Department of Obstetrics, Gynecology & Reproductive Sciences and Co-Director of Gynecologic Oncology Research at Magee-Womens Hospital of UPMC.
From an analyst’s perspective:
The stock price of AIM ImmunoTech Inc [AIM] has been fluctuating between $0.32 and $0.75 over the past year. AIM ImmunoTech Inc [AMEX: AIM] shares were valued at $0.56 at the most recent close of the market.
Analyzing the AIM fundamentals
The AIM ImmunoTech Inc [AMEX:AIM] reported sales of 0.20M for trailing twelve months, representing a surge of 16.07%. Gross Profit Margin for this corporation currently stands at -0.36% with Operating Profit Margin at -156.25%, Pretax Profit Margin comes in at -143.38%, and Net Profit Margin reading is -139.35%. To continue investigating profitability, this company’s Return on Assets is posted at -1.45, Equity is -1.15 and Total Capital is -2.93. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4942 points at the first support level, and at 0.4305 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6125, and for the 2nd resistance point, it is at 0.6671.
AIM ImmunoTech Inc [AIM] reported earnings per share of -$0.26 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.15/share, meaning a difference of -$0.11 and a surprise factor of -73.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.16 per share as compared to estimates of -$0.11 per share, a difference of -$0.05 representing a surprise of -45.50%.
Ratios To Look Out For
It’s worth pointing out that AIM ImmunoTech Inc [AMEX:AIM]’s Current Ratio is 1.68. Also, the Quick Ratio is 1.68, while the Cash Ratio stands at 0.63. Considering the valuation of this stock, the price to sales ratio is 139.22, the price to book ratio is 2.87.
Transactions by insiders
Recent insider trading involved BRYAN NANCY, Director, that happened on Mar 21 ’24 when 38462.0 shares were purchased. Director, APPELROUTH STEWART completed a deal on Mar 15 ’24 to buy 90910.0 shares. Meanwhile, CEO & President Equels Thomas K bought 75758.0 shares on Mar 15 ’24.
